Zimmer Biomet (NYSE:ZBH) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Zimmer Biomet (NYSE:ZBH) from a hold rating to a buy rating in a research note published on Saturday morning.

Several other analysts have also commented on ZBH. Wells Fargo & Company cut their target price on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 29th. Stifel Nicolaus decreased their price target on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating on the stock in a research report on Wednesday, April 29th. Barclays dropped their price target on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a report on Wednesday, April 29th. Citigroup cut their price objective on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a research report on Thursday, May 28th. Finally, Leerink Partners began coverage on Zimmer Biomet in a research note on Monday, April 13th. They set a “hold” rating and a $101.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have assigned a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $100.70.

Zimmer Biomet Trading Up 1.9%

Shares of ZBH stock opened at $91.35 on Friday. The stock has a 50-day simple moving average of $87.90 and a 200 day simple moving average of $89.81. The stock has a market capitalization of $17.67 billion, a P/E ratio of 23.73, a P/E/G ratio of 2.69 and a beta of 0.46. Zimmer Biomet has a fifty-two week low of $79.12 and a fifty-two week high of $108.29. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The firm had revenue of $2.09 billion for the quarter, compared to analysts’ expectations of $2.07 billion. During the same period in the previous year, the business earned $1.81 earnings per share. Zimmer Biomet’s revenue for the quarter was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, sell-side analysts expect that Zimmer Biomet will post 8.48 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio is currently 24.94%.

Insider Buying and Selling

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares in the company, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 1.28% of the company’s stock.

Hedge Funds Weigh In On Zimmer Biomet

A number of large investors have recently made changes to their positions in the business. Tema ETFs LLC grew its position in Zimmer Biomet by 39.8% during the second quarter. Tema ETFs LLC now owns 4,194 shares of the medical equipment provider’s stock valued at $361,000 after purchasing an additional 1,194 shares in the last quarter. Kentucky Trust Co lifted its position in Zimmer Biomet by 285.0% in the 2nd quarter. Kentucky Trust Co now owns 770 shares of the medical equipment provider’s stock worth $66,000 after buying an additional 570 shares in the last quarter. Handelsbanken Fonder AB lifted its position in Zimmer Biomet by 22.7% in the 2nd quarter. Handelsbanken Fonder AB now owns 152,064 shares of the medical equipment provider’s stock worth $13,091,000 after buying an additional 28,130 shares in the last quarter. Valeo Financial Advisors LLC boosted its stake in shares of Zimmer Biomet by 1.6% during the 2nd quarter. Valeo Financial Advisors LLC now owns 11,176 shares of the medical equipment provider’s stock valued at $962,000 after buying an additional 175 shares during the period. Finally, Wilsey Asset Management Inc. boosted its stake in shares of Zimmer Biomet by 4.7% during the 2nd quarter. Wilsey Asset Management Inc. now owns 421,867 shares of the medical equipment provider’s stock valued at $36,318,000 after buying an additional 18,883 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.